| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 3 | +214,284 | 43% | $7.00 | +$1,499,988 |
| Sells | 1 | -280,000 | 57% | $5.80 | -$1,624,000 |
| Net | +2 | -65,716 | -13% | -$124,012 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Aaron G.L. Fletcher | Director, 10%+ Owner | $111,175,297 | +$499,996 | +0.45% | 27 Jun 2025 |
| Leslie W. Kreis | Director, 10%+ Owner | $111,175,297 | +$499,996 | +0.45% | 27 Jun 2025 |
| Bios Equity COF, LP | Director, 10%+ Owner | $111,175,297 | +$499,996 | +0.45% | 27 Jun 2025 |
| TODD S. THOMSON | Director, 10%+ Owner | $16,003,463 | -$1,624,000 | -9.2% | 05 Jan 2026 |
| DANIEL M. SCHMITT | President, CEO and Director, Director | $4,851,010 | 13 Feb 2026 | ||
| Roger Sawhney | Director | 22 May 2025 | |||
| AMY L. RONNEBERG | Director | 22 May 2025 | |||
| Jason A. Keyes | Director | 22 May 2025 | |||
| Andrew Paul Mazar | Chief Operating Officer | 01 Apr 2025 | |||
| Bios 2024 Co-Invest, LP | Director, Member of 10% Group | 14 Aug 2024 | |||
| Bios Clinical Opportunity Fund, LP | 10%+ Owner | 12 Aug 2024 | |||
| PAUL J. LYTLE | Chief Financial Officer | 01 Apr 2025 | |||
| Dan Zabrowski | Director | 22 May 2025 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|